Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS

NCT07189936 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.

NCT NCT07189936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS
Lead sponsor
Vanderbilt University Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
December 18, 2025
Completion date
June 30, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid19, post-acute covid-19 syndrome, postural tachycardia syndrome (pots), sars cov 2 infection